These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

78 related items for PubMed ID: 8896786

  • 1. Clinical features of cocaine-induced panic.
    Louie AK, Lannon RA, Rutzick EA, Browne D, Lewis TB, Jones R.
    Biol Psychiatry; 1996 Nov 01; 40(9):938-40. PubMed ID: 8896786
    [No Abstract] [Full Text] [Related]

  • 2. Cocaine-associated panic attacks in methadone-maintained patients.
    Rosen MI, Kosten T.
    Am J Drug Alcohol Abuse; 1992 Nov 01; 18(1):57-62. PubMed ID: 1314016
    [Abstract] [Full Text] [Related]

  • 3. Ondansetron in the treatment of panic disorder.
    Schneier FR, Garfinkel R, Kennedy B, Campeas R, Fallon B, Marshall R, O'Donnell L, Hogan T, Liebowitz MR.
    Anxiety; 1996 Nov 01; 2(4):199-202. PubMed ID: 9160623
    [No Abstract] [Full Text] [Related]

  • 4. Personality dimensions in panic disorder before and after effective treatment.
    Starcevic V, Uhlenhuth EH.
    Anxiety; 1996 Nov 01; 2(2):95-8. PubMed ID: 9160608
    [No Abstract] [Full Text] [Related]

  • 5. Assessing the clinical utility of agoraphobia in the context of panic disorder.
    Schmidt NB, Cromer KR.
    Depress Anxiety; 2008 Nov 01; 25(2):158-66. PubMed ID: 17351905
    [Abstract] [Full Text] [Related]

  • 6. [Panic attacks and panic disorder--diagnosis, validation and therapy].
    Buller R, Benkert O.
    Nervenarzt; 1990 Nov 01; 61(11):647-57. PubMed ID: 2290450
    [No Abstract] [Full Text] [Related]

  • 7. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B.
    Depress Anxiety; 2007 Nov 01; 24(1):1-14. PubMed ID: 16894619
    [Abstract] [Full Text] [Related]

  • 8. [Clinical picture and treatment of agoraphobia with panic disorder].
    Litvintsev SV, Reznik AM, Kvashnina NV, Arbuzov AL, Krylov KE.
    Voen Med Zh; 2003 Jun 01; 324(6):53-9. PubMed ID: 12916423
    [No Abstract] [Full Text] [Related]

  • 9. Panic disorder subtypes: further clinical differences.
    Onur E, Alkin T, Tural U.
    Depress Anxiety; 2007 Jun 01; 24(7):479-86. PubMed ID: 17106872
    [Abstract] [Full Text] [Related]

  • 10. Marijuana precipitation of panic disorder with agoraphobia.
    Ströhle A, Müller M, Rupprecht R.
    Acta Psychiatr Scand; 1998 Sep 01; 98(3):254-5. PubMed ID: 9761416
    [Abstract] [Full Text] [Related]

  • 11. Treatment of cocaine-induced panic disorder.
    Louie AK, Lannon RA, Ketter TA.
    Am J Psychiatry; 1989 Jan 01; 146(1):40-4. PubMed ID: 2912249
    [Abstract] [Full Text] [Related]

  • 12. Korean panic disorder severity scale: construct validity by confirmatory factor analysis.
    Lim YJ, Yu BH, Kim JH.
    Depress Anxiety; 2007 Jan 01; 24(2):95-102. PubMed ID: 16845647
    [Abstract] [Full Text] [Related]

  • 13. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia.
    Mitte K.
    J Affect Disord; 2005 Sep 01; 88(1):27-45. PubMed ID: 16005982
    [Abstract] [Full Text] [Related]

  • 14. Recent developments in the understanding and pharmacotherapy of panic attacks.
    Liebowitz MR, Fyer AJ, Gorman J, Klein DF.
    Psychopharmacol Bull; 1986 Sep 01; 22(3):792-6. PubMed ID: 3797584
    [No Abstract] [Full Text] [Related]

  • 15. Issues in the assessment of treatment response in panic disorder with special reference to fluvoxamine.
    Ninan PT.
    J Clin Psychiatry; 1997 Sep 01; 58 Suppl 5():24-31. PubMed ID: 9184624
    [Abstract] [Full Text] [Related]

  • 16. Method for assessing the duration of therapeutic action and milligram equivalence of anxiolytics.
    Sheehan DV, Raj AB, Harnett-Sheehan K, Dorotheo J, Sheehan MF, Trehan R, Knapp E, Swiontek A, Coleman B.
    Anxiety; 1996 Sep 01; 2(1):40-6. PubMed ID: 9160598
    [No Abstract] [Full Text] [Related]

  • 17. EMDR for panic disorder with agoraphobia: comparison with waiting list and credible attention-placebo control conditions.
    Goldstein AJ, de Beurs E, Chambless DL, Wilson KA.
    J Consult Clin Psychol; 2000 Dec 01; 68(6):947-56. PubMed ID: 11142547
    [Abstract] [Full Text] [Related]

  • 18. [Clinical effect and tolerance of paxil (paroxetine) in management of panic disorders].
    Mosolov SN, Smulevich AB, Nuller IuL, Grigor'evskikh VS, Kostiukova EG, Kuzavkova MV, Koliutskaia EV, Andriushchenko AV, Zelenina EV, Kosinskiĭ VP, Kozlovskiĭ VL, Bykov SI, Pererva IG.
    Ter Arkh; 2000 Dec 01; 72(10):16-23. PubMed ID: 11220870
    [Abstract] [Full Text] [Related]

  • 19. [Panic-agoraphobic spectrum].
    Onur E, Alkin T, Monkul ES, Fidaner H.
    Turk Psikiyatri Derg; 2004 Dec 01; 15(3):215-23. PubMed ID: 15362006
    [Abstract] [Full Text] [Related]

  • 20. On the need for standardization in panic disorder treatment research: survey of the literature, 1980-1992.
    Weise RE, Shear MK, Maser JD.
    Anxiety; 1996 Dec 01; 2(6):257-64. PubMed ID: 9160633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.